REFERENCES
2. Damodaran S, Kyriakopoulos CE, Jarrard DF. Newly diagnosed metastatic prostate cancer: has the paradigm changed? Urol Clin North Am 2017;44:611-21.
3. Sartor AO. Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space. J Hematol Oncol 2011;4:18.
4. Hellerstedt B, Pienta K. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 2008;52:154-79.
5. Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 2018;378:1408-18.
6. Hussain M, Fizazi K, Saad F, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2018;378:2465-74.
7. Fizazi K, Shore N, Tammela TL, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2019;380:1235-46.
8. Leung DK, Chiu PK, Ng C, Teoh JY. Novel strategies for treating castration-resistant prostate cancer. Biomedicines 2021;9:339.
9. Scott LJ. Abiraterone acetate: a review in metastatic castration-resistant prostrate cancer. Drugs 2017;77:1565-76.
12. Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 2007;1:19-25.
13. New M, Olzscha H, La Thangue NB. HDAC inhibitor-based therapies: can we interpret the code. Mol Oncol 2012;6:637-56.
14. Singh BN, Zhang G, Hwa YL, Li J, Dowdy SC, Jiang SW. Nonhistone protein acetylation as cancer therapy targets. Expert Rev Anticancer Ther 2010;10:935-54.
15. Abbas A, Gupta S. The role of histone deacetylases in prostate cancer. Epigenetics 2008;3:300-9.
16. Conteduca V, Hess J, Yamada Y, Ku SY, Beltran H. Epigenetics in prostate cancer: clinical implications. Trans Androl Urol 2021;10:3104-16.
17. Crea F, Sun L, Mai A, et al. The emerging role of histone lysine demethylases in prostate cancer. Mol Cancer 2012;11:52.
18. Huang PH, Chen CH, Chou CC, et al. Histone deacetylase inhibitors stimulate histone H3 lysine 4 methylation in part via transcriptional repression of histone H3 lysine 4 demethylases. Mol Pharmacol 2011;79:197-206.
19. Orzan F, Pellegatta S, Pollani PL, et al. Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells. Neuropathol Appl Neurobiol 2011;37:381-394.
20. Nebbioso A, Carafa V, Benedetti R, Altuicci L. Trials with "epigenetic" drugs: an update. Mol Oncol 2012;6:657-82.
21. Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 2004;59:177-89.
22. Weichert W, Röske A, Gekeler V, et al. Histone deacetylases 1, 2, and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 2008;98:604-10.
23. Welsbie DS, Xu J, Chen Y, et al. Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res 2009;69:958-66.
24. Rana Z, Diermeier S, Hanif M, Rosengren RJ. Understanding failure and improving treatment using HDAC inhibitors for prostate cancer. Biomedicines 2020;8:22.
25. Kong D, Ahmad A, Bao B, Li Y, Banerjee S, Sarkar FH. Histone deacetylase inhibitors induce epithelial-to-mesenchymal transition in prostate cancer cells. PLoS ONE 2012;7:e45045.
26. Ververis K, Hiong A, Karagiannis TC, Licciardi PV. Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics 2013;7:47-60.
27. Gregoretti IV, Lee YM, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 2004;338:17-31.
28. Paris M, Porcelloni M, Binaschi M, Fattori D. Histone deacetylase inhibitors: from bench to bedside. J Med Chem 2008;51:1505-29.
29. Schobert R, Biersack B. Multimodal HDAC inhibitors with improved anticancer activity. Curr Cancer Drug Targets 2018;18:39-56.
30. Biersack B, Polat S, Höpfner M. Anticancer properties of chimeric HDAC and kinase inhibitors. Semin Cancer Biol 2020; doi: 10.1016/j.semcancer.2020.11.005.
31. Kaushik D, Vashistha V, Isharwal S, Sediqe SA, Lin MF. Histone deacetylase inhibitors in castration-resistant prostate cancer: molecular mechanism of action and recent clinical trials. Ther Adv Urol 2015;7:388-95.
32. Molife LR, Attard G, Fong PC, et al. Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Ann Oncol 2010;21:109-13.
33. Bradley D, Rathkopf D, Dunn R, et al. Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. Cancer 2009;115:5541-9.
34. Rathkopf D, Picus J, Hussain A, et al. A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol 2013;72:537-44.
35. Rathkopf D, Wong B, Ross R, et al. A phase I study of oral panobinostat (LBH589) alone and in combination with docetaxel (Doc) and prednisone in castration-resistant prostate cancer (CRPC). J Clin Oncol 2008;26:5152.
36. Ferrari A, Stein M, Alumkal, et al. A phase I/II randomized study of panobinostat and bicalutamide in castration-resistant prostate cancer (CRPC) patients progressing on second-line hormone therapy. J Clin Oncol 2011;29:156.
37. Ferrari AC, Alumkal JJ, Stein MN, et al. Epigenetic therapy with panobinostat combined with bicalutamide rechallenge in castration-resistant prostate cancer. Clin Cancer Res 2019;25:52-63.
38. Eigl BJ, North S, Winquist, et al. A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195. Invest New Drugs 2015;33:969-76.
39. Tang S, Lian X, Jiang J, et al. Tumor suppressive maspin-sensitized prostate cancer to drug treatment through negative regulating androgen receptor expression. Front Cell Dev Biol 2020;8:573820.
40. Fang Y, Fliss A, Robins D, Caplan A. Hsp90 regulates androgen receptor hormone binding affinity in vivo. J Biol Chem 1996;271:28697-702.
41. Gravina GL, Marampon F, Muzi P, et al. PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, Hsp90, and CRM1 in preclinical models of prostate cancer. Endocr Relat Cancer 2013;20:321-37.
42. Chen L, Meng S, Wang H, et al. Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Mol Cancer Ther 2005;4:1311-9.
43. Shen L, Ciesilski M, Ramakrishnan S, et al. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. PLoS One 2012;7:e30815.
44. Armstrong K, Robson CN, Leung HY. NF-κB activation upregulates fibroblast growth factor 8 expression in prostate cancer cells. Prostate 2006;66:1223-34.
45. Xu W, Yang Z, Lu N. A new role for the PI3K/Akt signaling pathway in the epithelial-mesenchymal transition. Cell Adh Migr 2015;9:317-24.
46. Ruscetti M, Dadashian E, Guo W, et al. HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer. Oncogene 2016;35:3781-95.
47. Pellacani D, Packer RJ, Frame FM, et al. Regulation of the stem cell marker CD133 is independent of promoter hypermethylation in human epithelial differentiation and cancer. Mol Cancer 2011;10:94.
48. Fialova B, Luzna P, Gursky J, Langova K, Kolar Z, Trtkova KS. Epigenetic modulation of AR expression in prostate cancer DU145 cells with the combination of sodium butyrate and 5’-aza-2’-deoxycytidine. Oncol Rep 2016;36:2365-74.
49. Pacheco MB, Camilo V, Lopes N, et al. Hydralazine and panobinostat attenuate malignant properties of prostate cancer cell lines. Pharmaceuticals 2021;14:670.
50. Felice F, Tombolini V, Marampon F, Musella A, Marchetti C. Defective DNA repair mechanisms in prostate cancer: impact of olaparib. Drug Des Devel Ther 2017;11:547-52.
51. Martin GA, Chen AH, Parikh K. A novel use of olaparib for the treatment of metastatic castration-recurrent prostate cancer. Pharmacotherapy 2017;37:1406-14.
52. Chao OS, Goodman Jr OB. Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP. Mol Cancer Res 2014;12:1755-66.
53. Yin L, Liu Y, Peng Y, et al. PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells. J Exp Clin Cancer Res 2018;37:153.
54. Park SE, Kim H-G, Kim DE, et al. Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signalin in castration-resistant prostate cancer. Invest New Drugs 2018;36:195-205.
55. Pfeiffer MJ, Mulders PF, Schalken JA. An in vitro model for preclinical testing of endocrine therapy combinations for prostate cancer. Prostate 2010;70:1524-32.
56. Drake JM, Graham NA, Stoyanova T, et al. Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression. Proc Natl Acad Sci U S A 2012;109:1643-8.
57. Vallo S, Mani J, Stastny M, et al. The prostate cancer blocking potential of the histone deacetylase inhibitor LBH598 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258. Invest New Drugs 2013;31:265-72.
59. Corno C, Arrighetti N, Ciusani E, et al. Synergistic interaction of histone deacetylase 6- and MEK-inhibitors in castration resistant prostate cancer cells. Front Cell Dev Biol 2020;8:610.
60. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006;6:729-34.
62. Wedel S, Hudak L, Seibel JM, et al. Inhibitory effects of the HDAC inhibitor valproic acidon prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001. Life Sci 2011;88:418-24.
63. Wedel S, Hudak L, Seibel JM, et al. Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells. Clin Exp Metastasis 2011;28:479-91.
64. Tsaur I, Hudak L, Makarevic J, et al. Intensified antineoplastic effect by combining an HDAC-inhibitor, an mTOR-inhibitor and low dose interferon alpha in prostate cancer cells. J Cell Mol Med 2015;19:1795-804.
65. Ellis L, Lehet K, Ramakrishnan S, et al. Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression. PLoS ONE 2011;6:e27178.
66. Ellwood-Yen K, Graeber TG, Wongvipat J, et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 2003;4:223-38.
67. Balakumaran BS, Porrello A, Hsu DS, et al. MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy. Cancer Res 2009;69:7803-10.
68. Holoch PA, Griffith TS. TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. Eur J Pharmacol 2009;625:63-72.
69. Kasman L, Lu P, Voelkel-Johnson C. The histone deacetylase inhibitors depsipeptide and MS-275, enhance TRIL gene therapy of LNCaP prostate cancer cells without adverse effects in normal prostate epithelial cells. Cancer Gene Ther 2007;14:327-34.
70. Kasman L, Oicescu G, Voelkel-Johnson C. Histone deacetylase inhibitors restore cell surface expression of the Coxsackie adenovirus receptor and enhance CMV promoter activity in castration-resistant prostate cancer cells. Prostate Cancer 2012;2012:137163.
71. Chen Z, Wang X, Yang X, et al. Imaging assisted evaluation of antitumor efficacy of a new histone deacetylase inhibitor in the castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 2021;48:53-66.
72. Fu RG, Sun Y, Sheng WB, Liao DF. Designing multi-targeted agents: an emerging anticancer drug discovery paradigm. Eur J Med Chem 2017;136:195-211.
73. Bérubé G. An overview of molecular hybrids in drug discovery. Exp Opin Drug Discov 2016;11:281-305.
74. Rosati R, Chen B, Patki M, et al. Hybrid enzalutamide derivatives with histone deacetylase inhibitor activity decrease heat shock protein 90 and androgen receptor levels and inhibit viability in enzalutamide-resistant prostate cancer cells. Mol Pharmacol 2016;90:225-37.
75. Hu W-Y, Xu L, Chen B, et al. Targeting prostate cancer cells with enzalutamide-HDAC inhibitor hybrid drug 2-75. Prostate 2019;79:1166-79.
76. Lai C-J, Bao R, Tao X, et al. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. Cancer Res 2010;70:3647-56.
77. Sun H, Mediwala SN, Szafran AT, Mancini MA, Marcelli M. CUDC-101, a novel inhibitor of full-length androgen receptor (flAR) and androgen receptor variant 7 (AR-V7) activity: mechanisms of action and in vivo efficacy. HORM CANC 2016;7:196-210.
78. Li X, Kamenecka TM, Cameron MD. Cytochrome P450-mediated bioactivation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile. Drug Metab Dispos 2010;38:1238-45.
79. Gass-Jégu F, Gschwend A, Gairard-Dory AC, et al. Gastrointestinal perforations in patients treated with erlotinib: a report of two cases with fatal outcome and literature review. Lung Cancer 2016;99:76-78.
80. Galloway TJ, Wirth LJ, Covelas AD, et al. A phase I study of CUDC-101, a multitarget inhibitor of HDACs, EGFR, and HER2, in combination with chemoradiation in patients with head and neck squamous cell carcinoma. Clin Cancer Res 2015;21:1566-73.
81. Wu CP, Hsiao SH, Su CY, et al. Human ATP-Binding Cassette transporters ABCB1 and ABCG2 confer resistance to CUDC-101, a multi-acting inhibitor of histone deacetylase, epidermal growth factor receptor and human epidermal growth factor receptor 2. Biochem Pharmacol 2014;92:567-76.
82. Yanase K, Tsukahara S, Asada S, Ishikawa E, Imai Y, Sugimoto Y. Gefitinib reverses breast cancer resistance protein-mediated drug resistance. Mol Cancer Ther 2004;3:1119-25.
83. Leggas M, Panetta JC, Zhuang Y, et al. Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer Res 2006;66:4802-7.
84. Goehringer N, Biersack B, Peng Y, et al. Anticancer activity and mechanisms of action of new chimeric EGFR/HDAC-inhibitors. Int J Mol Sci 2021;22:8432.
85. Qian C, Lai C-J, Bao R, et al. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling. Clin Cancer Res 2012;18:4104-13.
86. Hu C, Xia H, Bai S, et al. CUDC-907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: antitumor activity and molecular mechanism of action. J Cell Mol Med 2020;24:7239-53.
87. Landsburg DJ, Barta SK, Ramchandren R, et al. Fimepinostat (CUDC-907) in patients with relapsed diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses. Br J Haematol 2021;195:201-9.
